Kevin Weil, the former chief product officer at OpenAI, has launched a startup backed by $215 million, Bloomberg reported.
The venture sits in the “AI for science” category. Its focus is gathering specialized scientific data to make AI models better at research.
From stealth target to nine-figure launch
The company has been operating in stealth mode. Details about its product and its name have stayed largely under wraps.
Earlier, the raise had been described as a round of about $150 million. That round targeted a valuation of at least $750 million. At that stage, the terms were not yet finalized.
The $215 million figure Bloomberg reported sits well above that earlier $150 million ask. Final investor names and the valuation behind the $215 million have not been publicly confirmed. For now, the $750 million floor remains the only valuation marker on record.
Who is Kevin Weil
Weil left OpenAI in April 2026. During his time there, he served as chief product officer and later as VP for Science.
In that science role, he led initiatives including Prism. That project brought advanced AI models directly into scientific workflows.
His resume before OpenAI includes key product roles at Twitter and Meta. He also worked at Planet Labs, the satellite imaging company, where he contributed significantly to its public listing.
Part of a broader AI-for-science wave
Weil is not alone in this move. Alumni from OpenAI and Google have been launching their own companies built around using AI for scientific breakthroughs.
Those efforts span areas like drug discovery and autonomous research experiments.
What this means
Seed-stage valuations of at least $750 million leave little room for error. A company priced that richly before launching a product needs to deliver results that justify the number.
The gap between the earlier $150 million target and the reported $215 million is worth watching. Final terms, the investor lineup, and the valuation attached to the larger figure will show how much conviction backers actually have.
Once the company exits stealth, the market will learn whether it plans to sell data, sell models, or partner directly with research organizations.
Disclosure: This article was edited by Diego Almada Lopez. For more information on how we create and review content, see our Editorial Policy.